These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21826673)

  • 61. Clinicopathologic features of familial nonmedullary thyroid carcinoma.
    Fan YF; Zhang B; Yang X; Shang ZH; Liu HF; Xie Y; Liu YW; Gao WS; Wu Q; Li XY
    Chin Med J (Engl); 2015 Apr; 128(8):1037-41. PubMed ID: 25881596
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular study of signaling-pathway genes in experimental rat thyroid carcinoma.
    Carmona-López MI; De Miguel M; Galera-Ruiz H; Ríos-Moreno MJ; Fernández A; Galera-Davidson H
    Endocr Res; 2012; 37(4):188-96. PubMed ID: 22630346
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.
    Cantara S; Marzocchi C; Castagna MG; Pacini F
    J Endocrinol Invest; 2017 May; 40(5):557-560. PubMed ID: 27873212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
    Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
    Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
    Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
    Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
    [TBL] [Abstract][Full Text] [Related]  

  • 66. N-ras mutation of thyroid tumor with special reference to the follicular type.
    Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
    Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
    Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
    [No Abstract]   [Full Text] [Related]  

  • 68. [Gene abnormalities in thyroid cancer].
    Namba H; Yamashita S
    Nihon Rinsho; 2007 Nov; 65(11):1967-72. PubMed ID: 18018556
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.
    Vasko V; Ferrand M; Di Cristofaro J; Carayon P; Henry JF; de Micco C
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2745-52. PubMed ID: 12788883
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in the MEN1 gene.
    Nord B; Larsson C; Wong FK; Wallin G; Teh BT; Zedenius J
    Genes Chromosomes Cancer; 1999 Sep; 26(1):35-9. PubMed ID: 10441003
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ras oncogene mutations in benign and malignant thyroid neoplasms.
    Karga H; Lee JK; Vickery AL; Thor A; Gaz RD; Jameson JL
    J Clin Endocrinol Metab; 1991 Oct; 73(4):832-6. PubMed ID: 1890154
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
    Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
    Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
    Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
    Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
    Diquigiovanni C; Bonora E
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
    de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
    Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.
    Vriens MR; Suh I; Moses W; Kebebew E
    Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Risk factors of thyroid cancer].
    Khaziev VV; Shtandel' SA; Bariliak IR
    Lik Sprava; 2009; (3-4):63-7. PubMed ID: 19960590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.